AMSTERDAM, The Netherlands, June 19 /PRNewswire/ -- Agendia BV has announced the official opening of the company's new headquarters yesterday at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406. The Grand Opening ceremony was officiated by Dr. Rene Bernards, Chief Scientific Officer at Agendia and the Honourable Director General Mrs. R.M. Bergkamp, on behalf of the Honourable Mrs. Maria van der Hoeven, Minster of Economic Affairs for The Netherlands.
"Agendia has a distinguished history of providing exceptional high quality diagnostic testing services that provide valuable information for cancer patients and the physicians who treat them," said Dr. Bernhard Sixt, Agendia's president & chief executive officer (CEO). "The expanded capacity of our laboratories at our new location will allow us to meet the growing worldwide demand for our clinical services as we expand into major markets, enhancing the company's ability to serve the healthcare community."
The new facilities offer 13,000 square feet of laboratory and office space that will support the company's molecular diagnostic cancer testing services and research activities.
"Additionally, this move proves our ability to replicate our FDA-cleared and CLIA-certified laboratory in a new location in just 4 months," said Dr. Jan Groen, vice president and chief operating officer (COO) at Agendia. "The increased laboratory space will also allow the company to expand our research and product development capabilities to enhance commercialization of emerging diagnostic discoveries in cancer."
Currently, Agendia offers three test services through its expanded laboratories, including MammaPrint(R), based on the Amsterdam 70-gene profile that indicates risk of recurrence for breast cancer tumors and the first in vitro diagnostic multi index variant assay (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA), and CupPrint(R), which identifies the origin of metastases with unknown primary tumors (Cancer of Unknown Primary).
Agendia, located in Amsterdam, The Netherlands, is a world leader in
gene expression analysis-based diagnostics with three products on the
market. The company focuses on the development and commercialization of
diagnostic tests using tumor gene expression profiling. Agendia was the
first company to commercialize a prognostic test -- MammaPrint(R) -- that
predicts the risk of breast cancer recurrence. Agendia maintains close ties
with several leading academic centers to develop state of the art
diagnostic tests for cancer. Agendia also offers its expertise to pharma
companies focusing on development of highly effective personalized drugs in
the area of oncology. For more information on Agendia, please visit
* CupPrint(R) is based on a license to the TUO database of AviaraDx
For Agendia - EU & non-U.S.-based Media:
Dr. Bernhard Sixt
President and Chief Executive Officer
For Agendia - U.S. Media:
Ogilvy Public Relations Worldwide
|SOURCE Agendia BV|
Copyright©2008 PR Newswire.
All rights reserved